Literature DB >> 20673557

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

James G Waxmonsky1, Daniel A Waschbusch, William E Pelham, Lillian Draganac-Cardona, Bryan Rotella, Lynn Ryan.   

Abstract

OBJECTIVE: To evaluate the effects of atomoxetine alone and in combination with behavior therapy on the school functioning of children with attention-deficit/hyperactivity disorder (ADHD). Most atomoxetine studies have not assessed school functioning other than by measuring the change in ADHD symptoms. Combining behavior therapy with atomoxetine may be particularly beneficial for the academic domain as medication has not been found to produce sustained benefits in this realm. However, there is little research examining the effects of combining atomoxetine and behavior therapy.
METHOD: In an 8-week open-label trial, 56 children aged 6-12 years with ADHD diagnosed according to DSM-IV-TR were randomly assigned to receive atomoxetine and behavior therapy or atomoxetine alone. Behavior therapy consisted of an 8-week parenting course, a child social skills course, and a teacher-implemented daily report card of classroom behavior. The primary outcome was direct observation of the subject's classroom behavior. Secondary outcomes included change in ADHD symptoms and functioning at home and school. All data were collected between March 2007 and May 2008.
RESULTS: Classroom observations showed that atomoxetine decreased rule violations (P < .0001). Moreover, atomoxetine was associated with significant improvements in ADHD and oppositional defiant disorder symptoms at home and school and enhanced functioning in both domains (Impairment Rating Scale: all P < .001). Combined treatment led to greater improvements in parent-rated symptoms of inattention (P < .01), problem behaviors (P < .001), and academic impairment (P < .05). However, teachers did not report significant group differences.
CONCLUSIONS: Atomoxetine improved ADHD symptoms and classroom functioning as measured by parents, teachers, and direct observation. The addition of behavior therapy led to further improvements at home but not at school. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00918567. © Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673557     DOI: 10.4088/JCP.09m05496pur

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

1.  Physical exercise alleviates ADHD symptoms: regional deficits and development trajectory.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-18       Impact factor: 3.911

Review 2.  The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.

Authors:  Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

3.  Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

Authors:  Jeffery N Epstein; Margaret D Weiss
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-29

Review 4.  Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?

Authors:  Raman Baweja; Richard E Mattison; James G Waxmonsky
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

5.  Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Robert L Findling; Keith McBurnett; Carla White; Sharon Youcha
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-06       Impact factor: 2.576

6.  A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Authors:  Nicola Savill; Chris J Bushe
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-01-10       Impact factor: 3.033

7.  Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years.

Authors:  Ole Jakob Storebø; Mette Elmose Andersen; Maria Skoog; Signe Joost Hansen; Erik Simonsen; Nadia Pedersen; Britta Tendal; Henriette E Callesen; Erlend Faltinsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

Review 8.  Peer Inclusion in Interventions for Children with ADHD: A Systematic Review and Meta-Analysis.

Authors:  Reinie Cordier; Brandon Vilaysack; Kenji Doma; Sarah Wilkes-Gillan; Renée Speyer
Journal:  Biomed Res Int       Date:  2018-03-18       Impact factor: 3.411

9.  Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder.

Authors:  Michael R Kohn; Tracey W Tsang; Simon D Clarke
Journal:  Clin Med Insights Pediatr       Date:  2012-11-05

10.  Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.

Authors:  Jennifer A Janusz; Bonita P Klein-Tasman; Jonathan M Payne; Pamela L Wolters; Heather L Thompson; Staci Martin; Peter de Blank; Nicole Ullrich; Allison Del Castillo; Maureen Hussey; Kristina K Hardy; Kristina Haebich; Tena Rosser; Mary Anne Toledo-Tamula; Karin S Walsh
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.